Last reviewed · How we verify
Chemotherapy, gemcitabine
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cancer cell death.
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cancer cell death. Used for Pancreatic cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | Chemotherapy, gemcitabine |
|---|---|
| Also known as | all brands of gemcitabine are allowed |
| Sponsor | University of Erlangen-Nürnberg Medical School |
| Drug class | Nucleoside analog; antimetabolite chemotherapy |
| Target | Ribonucleotide reductase; DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a deoxycytidine analog that is phosphorylated intracellularly to its active form. It inhibits ribonucleotide reductase, reducing deoxyribonucleotide pools, and is incorporated into DNA during replication, leading to chain termination and apoptosis. It is particularly effective against rapidly dividing cells.
Approved indications
- Pancreatic cancer
- Non-small cell lung cancer
- Breast cancer
- Ovarian cancer
- Bladder cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Fatigue
- Fever
- Rash
- Hepatotoxicity
- Hemolytic uremic syndrome (rare)
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy, gemcitabine CI brief — competitive landscape report
- Chemotherapy, gemcitabine updates RSS · CI watch RSS
- University of Erlangen-Nürnberg Medical School portfolio CI